Deep-Tech Oncology
Precision Plasma Medicine for Enhancing Cancer Therapy
Our Expertise
Pioneers in Bioengineering & Plasma Medicine
Our leadership team brings together deep expertise across plasma physics, biomaterials, and translational oncology, united by a shared vision to transform cancer treatment.
Adrià Barceló
Prof. Cristina Canal
Dr. Cédric Labay
CEO. Materials Engineer with extensive experience in biomaterials & plasma medicine for cancer therapies, complemented by strong training in regulatory affairs, IP strategy, business development & technology transfer.
CSO & Full Professor in the Dept. of Materials Science Engineering at UPC. Head of the PlasmaMED Lab research group, integrated in the Institute for Research and Innovation in Health (IRIS). Specialized in cold plasma interactions for biomedical applications.
CTO. With a PhD. & over 10-years research expertise in plasma technology for biomedical applications, with extensive knowledge in tech transfer, valorization strategies, network building & business development.
Our Commitment
Advancing Precision in Localized Cancer Therapeutics
We are dedicated to creating measurable societal value by translating complex physics into clinical solutions. Our engineered biomaterials aim to deliver high-precision, localized treatment options, minimizing systemic toxicity and maximizing therapeutic impact where it matters the most.


PlasmOnCo was founded at the unique intersection of cold atmospheric plasma physics and advanced bioengineering. Ten years ago, an unconventional idea took shape in the PlasmaMedLab, part of Biomaterials, Biomechanics and Tissue Engineering Research Group (BBT-UPC). After a decade of research and perseverance, with the contribution of all the talents who have been part of the research team and the support of several funding programs — including an European Research Council (ERC) Starting Grant and an ERC Proof of Concept — we have turned that idea into a promising therapeutic approach.
Backed by strong scientific evidence, resulting in multiple publications in high-impact scientific journals, and positive feedback from clinicians and healthcare professionals, our pioneering research laid the groundwork for a new class of bio-interactive materials, designed specifically to overcome the systemic limitations of traditional chemotherapy and enhance treatment efficacy for solid tumors.
Support & Grants
Our translational milestones and scientific background are backed by competitive public research grants, deep-tech development programs, and leading clinical innovation networks.
Deep-Tech Programs
Competitive Grants
Institutional Backing
Selected for elite biotech acceleration cohorts that provide strategic mentoring, technical & business skills, and regulatory guidance for translational oncology ventures.
Supported by competitive public science grants and tech-transfer funding dedicated to advancing cold atmospheric plasma applications in targeted drug delivery for biomedical applications.
Partnered with premier bio-engineering centers and oncology research groups to validate therapeutic efficacy across rigorous pre-clinical testing protocols.


Support & Grants
Our translational milestones and scientific background are backed by competitive public research grants, deep-tech development programs, and leading clinical innovation networks.
Deep-Tech Programs
Competitive Grants
Institutional Backing
Selected for elite biotech acceleration cohorts that provide strategic mentoring, technical & business skills, and regulatory guidance for translational oncology ventures.
Supported by competitive public science grants and tech-transfer funding dedicated to advancing cold atmospheric plasma applications in targeted drug delivery for biomedical applications.
Partnered with premier bio-engineering centers and oncology research groups to validate therapeutic efficacy across rigorous pre-clinical testing protocols.















Join us in advancing precision oncology.
